Shigekazu Nagata

This inventor holds 23 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: Osaka Bioscience Institute, Mochida Pharmaceutical Co., Ltd., Kyoto University. Active years: 1993-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shigekazu Nagata. Retrieved from https://idiyas.com/inventor/shigekazu-nagata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 1)

% Patents Active = 73.9

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 237(Granted Patents)

Location History:

Osaka-fu, JP (2000 - 2005)
Minoo, JP (2003 - 2005)
Kyoto-fu, JP (2009)
Osaka, JP (2006 - 2013)
Kyoto, JP (2016 - 2018)
Suita, JP (1993 - 2023)

Company Filing History:

10 out of 19

Osaka Bioscience Institute

patents

9 out of 229

Mochida Pharmaceutical Co., Ltd.

Japan Science and Technology Agency

patents

5. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2023

Loading Chart...

Areas of Expertise:

ATP11C

CDC50A

XKR8

TMEM16

Apoptosis

Fas Ligand

Graft Versus Host Disease

Inflammatory Intestinal Disease

Antibodies

Human Cell Surface Antigen

CD4 Lymphocytes

Granulocyte Colony-Stimulating Factor

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11692999 - Method of screening ATP11C or CDC50A inhibitor (2023-07-04),

2. 11073510 - Method of screening ATP11C or CDC50A inhibitor (2021-07-27),

3. 10295528 - Method of screening ATP11C or CDC50A inhibitor (2019-05-21),

4. 9857357 - Method of screening modulator of XKR8 (2018-01-02),

5. 9453835 - Method for screening a modulator of a TMEM16 family member (2016-09-27),

6. 8603455 - Removal promoters and inhibitor for apoptosis cells in vivo (2013-12-10),

7. 8398984 - Removal promoters and inhibitor for apoptosis cells in vivo (2013-03-19),

8. 7622554 - FAS ligand derived polypeptides (2009-11-24),

9. 7128905 - Method of treating graft versus host disease by administration of a Fas antagonist (2006-10-31),

10. 6953847 - Fas antigen derivative (2005-10-11),

11. 6951919 - Fas ligand derivative (2005-10-04),

12. 6949360 - DNA coding for human cell surface antigen (2005-09-27),

13. 6897295 - Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides (2005-05-24),

14. 6562342 - Preventives/remedies for inflammatory intestinal disease (2003-05-13),

15. 6348334 - DNA encoding Fas ligand (2002-02-19),

Title: Shigekazu Nagata: Innovator in Pharmacological Research

Introduction

Shigekazu Nagata is an accomplished inventor based in Suita, Japan, known for his substantial contributions to pharmacological research. With a total of 23 patents to his name, Nagata has focused on developing innovative methods that enhance our understanding of cellular processes and potential therapeutic applications.

Latest Patents

Among Shigekazu Nagata's latest innovations is a patent that details a method for screening inhibitors of ATP11C or CDC50A. This invention involves determining the exposure of phosphatidylserine on the cell surface, the engulfment of cells by macrophages, or the cleavage of ATP11C by caspase. Furthermore, the invention also encompasses a method for inducing the engulfment of cells by macrophages through the inhibition of ATP11C or CDC50A. This groundbreaking work holds the potential to advance research in cellular clearance and therapeutic interventions.

Career Highlights

Throughout his career, Nagata has worked with reputable organizations, such as the Osaka Bioscience Institute and Mochida Pharmaceutical Co., Ltd. His experiences within these institutions have enabled him to hone his skills and deepen his knowledge in the field, leading to the inception of significant innovations in drug discovery and development.

Collaborations

In the course of his professional journey, Shigekazu Nagata has collaborated with esteemed colleagues, including Norio Nakamura and Takashi Suda. These partnerships have fostered an environment of creativity and shared expertise, driving forward the research and development of his remarkable inventions.

Conclusion

Shigekazu Nagata stands as a prominent figure in the realm of pharmacological innovation, exemplified by his impressive portfolio of patents and collaborative efforts. His work not only advances the scientific community's understanding of cellular mechanisms but also paves the way for future therapeutic developments. As he continues to explore new frontiers in research, his contributions will undoubtedly leave a lasting impact on the field.

Profile summary based on public USPTO records.